0.436
price down icon5.22%   -0.024
after-market Handel nachbörslich: .44 0.004 +0.92%
loading
Schlusskurs vom Vortag:
$0.46
Offen:
$0.4577
24-Stunden-Volumen:
68,662
Relative Volume:
0.29
Marktkapitalisierung:
$17.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.52M
KGV:
-0.2086
EPS:
-2.09
Netto-Cashflow:
$-45.03M
1W Leistung:
-6.38%
1M Leistung:
-11.45%
6M Leistung:
-43.45%
1J Leistung:
-70.93%
1-Tages-Spanne:
Value
$0.4263
$0.47
1-Wochen-Bereich:
Value
$0.4263
$0.4919
52-Wochen-Spanne:
Value
$0.224
$1.8199

Nextcure Inc Stock (NXTC) Company Profile

Name
Firmenname
Nextcure Inc
Name
Telefon
240-399-4900
Name
Adresse
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Name
Mitarbeiter
43
Name
Twitter
@nextcureinc
Name
Nächster Verdiensttermin
2025-03-07
Name
Neueste SEC-Einreichungen
Name
NXTC's Discussions on Twitter

Vergleichen Sie NXTC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NXTC
Nextcure Inc
0.436 17.26M 0 -58.52M -45.03M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-11-04 Herabstufung Ladenburg Thalmann Buy → Neutral
2022-03-01 Eingeleitet Ladenburg Thalmann Buy
2021-03-05 Hochstufung Truist Hold → Buy
2021-01-15 Herabstufung BofA Securities Neutral → Underperform
2020-07-16 Hochstufung The Benchmark Company Hold → Buy
2020-07-13 Herabstufung ROTH Capital Buy → Neutral
2020-07-13 Herabstufung SunTrust Buy → Hold
2020-06-01 Herabstufung BofA/Merrill Buy → Neutral
2020-06-01 Herabstufung The Benchmark Company Buy → Hold
2020-05-26 Eingeleitet JMP Securities Mkt Outperform
2020-03-24 Eingeleitet The Benchmark Company Buy
2020-03-02 Eingeleitet ROTH Capital Buy
2020-01-13 Eingeleitet SunTrust Buy
2019-12-05 Eingeleitet Needham Buy
2019-11-26 Eingeleitet BTIG Research Buy
2019-07-09 Eingeleitet BofA/Merrill Buy
2019-06-03 Eingeleitet Morgan Stanley Overweight
2019-06-03 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Nextcure Inc Aktie (NXTC) Neueste Nachrichten

pulisher
Jun 17, 2025

Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com

Jun 17, 2025
pulisher
Jun 17, 2025

Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter

Jun 17, 2025
pulisher
Jun 17, 2025

NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Finance

Jun 17, 2025
pulisher
Jun 16, 2025

NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Simcere Enters Strategic License Agreement with NextCure for Oncology Advancements - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Lands Massive $745M Deal for Revolutionary Cancer Drug: Phase 1 Trials Starting Q3 2025 - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025 - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Is Lucid Stock a Millionaire-Maker? - The Globe and Mail

Jun 16, 2025
pulisher
Jun 12, 2025

JD.com Underperforms Industry in 3 Months: Should You Book Profits? - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

Whitbread (LON:WTB) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Can Shopify's Expanding Merchant Base Sustain Its Growth Momentum? - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Baidu Bets Big on AI: Is the Cloud Business Finally Paying Off? - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

SFIX Q3 Loss Narrower Than Expected, FY25 Outlook Raised, Stock Up 8% - The Globe and Mail

Jun 11, 2025
pulisher
Jun 10, 2025

COIN Outpaces Industry in 3 Months: Time to Buy the Stock? - The Globe and Mail

Jun 10, 2025
pulisher
Jun 05, 2025

Power Corporation's President and Chief Executive Officer R. Jeffrey Orr to speak at the Scotiabank Financials Summit - The Globe and Mail

Jun 05, 2025
pulisher
Jun 05, 2025

Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews

Jun 05, 2025
pulisher
Jun 05, 2025

Best Dollar Store Stock to Buy: Dollar Tree or Dollar General? - The Globe and Mail

Jun 05, 2025
pulisher
Jun 02, 2025

2 No-Brainer Growth Stocks to Buy in June - The Globe and Mail

Jun 02, 2025
pulisher
May 31, 2025

The Next Stock I'm Buying? - The Globe and Mail

May 31, 2025
pulisher
May 29, 2025

NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 - Insider Monkey

May 29, 2025
pulisher
May 29, 2025

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - The Manila Times

May 29, 2025
pulisher
May 29, 2025

NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025 - Nasdaq

May 29, 2025
pulisher
May 29, 2025

First-in-Human Trial: NextCure's Revolutionary Cancer Drug Shows Promise Against 5 Hard-to-Treat Tumors - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews

May 29, 2025
pulisher
May 23, 2025

Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - Yahoo Finance

May 23, 2025
pulisher
May 21, 2025

Here's How I'd Invest $10,000 Today - The Globe and Mail

May 21, 2025
pulisher
May 20, 2025

Grant Williamson appointed as Canada Leader for Willis - The Globe and Mail

May 20, 2025
pulisher
May 17, 2025

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’ - The Globe and Mail

May 17, 2025
pulisher
May 14, 2025

Is Enbridge Stock Still Worth Owning After Strong Q1 Earnings? - The Globe and Mail

May 14, 2025
pulisher
May 13, 2025

Is Archer Aviation Stock (ACHR) a “Buy” Ahead of Q1 Earnings? - The Globe and Mail

May 13, 2025
pulisher
May 02, 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 02, 2025
pulisher
May 02, 2025

NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025
pulisher
May 02, 2025

NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks

May 02, 2025
pulisher
May 01, 2025

NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

NextCure, Inc. SEC 10-Q Report - TradingView

May 01, 2025
pulisher
May 01, 2025

NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan

May 01, 2025
pulisher
Apr 28, 2025

NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

Apr 28, 2025

Finanzdaten der Nextcure Inc-Aktie (NXTC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):